Patent · US Active

Methods and compositions for treatment of a genetic condition

US10196652B2 · kind B2 · utility

11Cited by

32References

21Claims

0Family size

Assignee

Sangamo Therapeutics, Inc. · US

Inventors

Anthony J. Conway · Chatfield, US
Gregory J. Cost · Berkeley, US
Russell DeKelver · Daly City, US
Edward J. Rebar · Richmond, US
Andreas Reik · Richmond, US
Fyodor Urnov · Richmond, US
Jianbin Wang · Richmond, US
H. Steve Zhang · Richmond, US

Key dates

Filing date	Jan 16, 2018
Grant date	Feb 5, 2019
Priority date	—
Expiry date	Jan 26, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Y301/21004
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

Methods and compositions comprising a CRISPR/Cas nuclease that cleaves a T cell receptor (TCR) gene and/or human leukocyte (HLA) gene, the nuclease comprising a cleavage domain and a single guide RNA that binds to a target site in the TCR and/or HLA gene.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.